Discovery of Thieno[3,2- b]pyridine-5-carboxamide and 2,3-Difluorobenzamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5

  • ACS Med Chem Lett. 2025 Apr 22;16(5):865-874. doi: 10.1021/acsmedchemlett.5c00119.
Katherine E Crocker  1  2 Scott H Henderson  1  2 Rory A Capstick  1  2 David L Whomble  1  2 Aaron M Bender  1  2 Andrew S Felts  1  2 Changho Han  1  2 Julie L Engers  1  2 Natasha B Billard  1  2 Mallory A Maurer  1  2 Hyekyung P Cho  1  2 Alice L Rodriguez  1  2 Colleen M Niswender  1  2  3  4  5 Jordan O'Neill  1  2 Katherine J Watson  1  2 Sichen Chang  1  2 Anna L Blobaum  1  2 Olivier Boutaud  1  2 Weimin Peng  2 Jerri M Rook  2 P Jeffrey Conn  1  2  5 Craig W Lindsley  1  2  6  3 Kayla J Temple  1  2
Affiliations
  • 1. Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • 2. Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
  • 3. Department of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • 4. Vanderbilt Kennedy Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
  • 5. Vanderbilt Brain Institute, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
  • 6. Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.
Abstract

This Letter describes the discovery of novel mGlu5 NAMs VU6031545 and VU6024945. Starting from previously reported picolinamide compounds, a structure-activity relationship study of various core isosteres was conducted, leading to the identification of thieno[3,2-b]pyridine-5-carboxamide and 2,3-difluorobenzamide as competent core replacements. These compounds are highly potent as well as brain penetrant with an IVIVC agreement and improved oral bioavailability in rats.

Products